Stallergenes' grass allergy drug wins FDA approval

04/1/2014 | Reuters

The FDA has approved Stallergenes' oral immunotherapy drug Oralair as a treatment for grass allergies. The drug, which contains extracts from five grass pollens, is the first immunotherapy pill approved for this indication in the U.S. Stallergenes' partner Greer Laboratories will market Oralair in the U.S.

View Full Article in:

Reuters

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Senior Director, Research
America's Health Insurance Plans (AHIP)
Washington, DC
Stop Loss Sales Executive
Blue Cross Blue Shield of MA
Boston, MA
Regional Director, Southeastern Region - State Affairs
America's Health Insurance Plans (AHIP)
Washington, DC
Field Representative-Oklahoma and Kansas
National Rural Electric Cooperative Association (NRECA)
Multiple Locations, SL_Multiple Locations
Market Intelligence Manager
Olympus Corporation of the Americas
Southborough, MA